Among them, drugs affecting the M-CSF/CSF1R axis and PI3Kγ are being tested in advanced solid tumors, glioblastoma, sarcoma, breast cancer, and renal cell carcinoma [11, 49, 56]. This evidence concerns the gene CSF1 and breast carcinoma.